Skip to Content

CSL Renames its Australian Operations

Melbourne, Australia — 05/12/2012 - CSL Limited (ASX:CSL) today announced that its plasma product operations in Australia will take on the name of its global plasma business, CSL Behring, and that the Company’s vaccine, pharmaceutical and diagnostics business will operate under the newly created name of bioCSL.

The new business names arise from a reorganisation of CSL Biotherapies which was announced with CSL’s full year results in August 2012. The new operating arrangements will take effect from 1 January 2013.

The integration of CSL’s Australian plasma product operations with CSL Behring will create a single, globally-integrated supply chain for the Company’s world-class portfolio of plasma therapies and its promising new recombinant products.

In parallel, the establishment of stand-alone business within the CSL Group to focus on vaccines, pharmaceuticals and diagnostics, including third party logistics, will provide a dedicated management structure for these distinct products and services.

“This reorganisation of CSL Biotherapies is being undertaken to better serve the needs of our customers and to optimise the overall performance of the CSL Group,” said Dr Brian McNamee, CSL Limited’s CEO and Managing Director.

“While the structure and name of our Australian operations are changing, both CSL Behring and bioCSL will remain fully committed to the reliable supply of high quality, life-saving medicines for Australians,” he said.

CSL Behring in Australia will be led by Dr Simon Green, a biochemist who has held a number of positions since joining CSL in 1998, most recently as Senior Vice President, Global R&D Product Development, where his focus has been on building CSL’s recombinant protein manufacturing capabilities. Prior to this, Simon spent several years as General Manager at CSL Behring’s manufacturing site in Germany and also led the global R&D program for CSL Behring.

bioCSL will be led by Dr John Anderson, who was formerly Vice President Commercial Operations of CSL Biotherapies and brings to the role more than 25 years of experience in the pharmaceutical industry. Since joining CSL in 2002 his achievements have included the successful commercialisation of cervical cancer vaccine GARDASIL® and the expansion of the Company’s in-licensed portfolio of products and partners.

Download this Release:
CSL Renames its Australian Operations (0.04Mb)

Media Contact:
Sharon McHale
Senior Director Public Affairs
Phone: +61 409 978 314


Posted: December 2012